Is cefepime indicated for treating Serratia infections?

Cefepime for Serratia Infections

Cefepime is indicated for Serratia infections and demonstrates in vitro activity against Serratia marcescens, though current guidelines suggest avoiding it for third-generation cephalosporin-resistant Enterobacterales (3GCephRE) infections.

FDA-Approved Indication and Activity

The FDA label explicitly lists Serratia marcescens among organisms for which cefepime demonstrates in vitro activity, with at least 90% of isolates exhibiting MICs at or below the susceptible breakpoint 1. Cefepime is approved for treating pneumonia, febrile neutropenia, urinary tract infections, skin infections, and complicated intra-abdominal infections caused by susceptible organisms 1.

Critical Guideline Caveat

However, the 2022 ESCMID guidelines—the most recent high-quality guidance—conditionally recommend against using cefepime for 3GCephRE infections (conditional recommendation, very low evidence) 2. This creates a nuanced clinical scenario requiring careful interpretation.

When to Use Cefepime for Serratia

Appropriate Scenarios:

• Ceftriaxone-susceptible Serratia infections: Recent evidence demonstrates cefepime is safe and effective for these cases 3, 4

  • A 2025 multicenter study found no difference in 30-day mortality between cefepime and carbapenem therapy for ceftriaxone-susceptible Serratia bacteremia (14.8% vs 0%, p=0.10) 3
  • Another 2025 study showed ceftriaxone itself was non-inferior to AmpC-stable therapies (including cefepime) for low-risk AmpC-harboring organisms like Serratia 4

• Confirmed AmpC-producing Serratia with adequate source control: A 2013 study using propensity-matched analysis found cefepime comparable to meropenem for invasive AmpC β-lactamase-producing infections (30-day mortality OR 0.63,95% CI 0.23-2.11) 5

Avoid Cefepime When:

• Third-generation cephalosporin resistance is documented: Use carbapenems (imipenem/meropenem for severe infections, ertapenem for non-septic shock BSI) 2
• Severe septic shock without susceptibility data: Empirically choose carbapenems over cefepime
• High-risk for resistance emergence: Patients with prior 3GC exposure or healthcare-associated infections

Clinical Decision Algorithm

1. Obtain susceptibility testing immediately
2. If ceftriaxone-susceptible: Cefepime is appropriate (or even ceftriaxone for low-risk cases)
3. If 3GC-resistant but cefepime-susceptible:
   • Severe infection/septic shock → Carbapenem (strong recommendation) 2
   • Mild-moderate infection with source control → Cefepime may be considered (based on 5)
4. If cefepime-resistant: Use carbapenem or newer agents per susceptibility

Important Caveats

• Resistance patterns vary: Up to 36% of Serratia isolates may show ESBL activity in certain populations, particularly IV drug users 6
• The ESCMID recommendation against cefepime is based on very low-quality evidence and predates recent comparative studies showing equivalence 2
• Carbapenem-sparing is important for stewardship: When Serratia is susceptible to cefepime and source control is adequate, cefepime represents a reasonable carbapenem-sparing option 5
• Recent real-world data (2025-2026) increasingly supports cefepime use for susceptible Serratia, contradicting the conservative 2022 guideline stance 7, 3, 4

Bottom line: Cefepime is FDA-indicated and clinically appropriate for Serratia infections when susceptibility is confirmed, particularly for ceftriaxone-susceptible isolates. Reserve carbapenems for 3GC-resistant cases or severe septic presentations pending susceptibilities.